Can a simple supplement heal newborn brains after birth injury?

NCT ID NCT07763145

Not yet recruiting Disease control Sponsor: Khyber Girls Medical College Source: ClinicalTrials.gov ↗

First seen Aug 13, 2026 · Last updated Aug 14, 2026 · Updated 1 time

Summary

This trial tests whether citicoline, a compound that may support brain cell repair, can improve outcomes in newborns with hypoxic-ischemic encephalopathy (HIE) — brain injury from oxygen deprivation at birth. About 86 infants with signs of birth asphyxia will receive either citicoline plus standard care or standard care alone. After 72 hours, researchers will compare brain blood flow and neurological severity scores to see if citicoline aids recovery.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: citicoline
What this could lead to: If effective, citicoline could offer a simple, accessible treatment to improve brain recovery in newborns with oxygen deprivation at birth.
What could go wrong: This is a small, early-stage trial, and results may not generalize. The drug's benefits are unproven, and potential side effects in newborns are not fully known.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HYPOXIC ISCHAEMIC ENCEPHALOPATHY (HIE) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

brain hypoxia - ischemia perinatal asphyxia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HYPOXIC ISCHAEMIC ENCEPHALOPATHY (HIE)

Contacts and locations

Locations

Hayatabad Medical Complex

Peshawar, KPK, 25000, Pakistan

More trials for these conditions

Other studies related to the condition(s) this trial covers.